35 Stocks Moving In Monday’s Mid-Day Session
Gainers
ZIVO Bioscience, Inc. (NASDAQ: ZIVO) jumped 145% to $6.86 after declining around 17% on Friday.
New CEO At Mirati Therapeutics
Amid data readouts from adagrasib, sitravatinib programs, Mirati Therapeutics Inc (NASDAQ:MRTX) has appointed David Meek as Chief Executive Officer, effective immediately. Related: Mirati…
Mirati Unveils Long-term Survival Data For Sitravatinib/Nivolumab Combo In Lung Cancer Patients
Mirati Therapeutics Inc (NASDAQ:MRTX) has announced results from a post hoc exploratory analysis of the Phase 2 study,…
Mirati Posts Adagrasib Data In KRAS-Mutated Lung Cancer, FDA Filing Now On The Cards
After data readout from KRAS drug adagrasib in colon cancer, Mirati Therapeutics Inc (NASDAQ:MRTX) has announced positive topline results from a Phase II…
Mirati Therapeutics Announces Phase 2 Topline Results For Investigational Adagrasib In Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, today announced positive topline results from the potentially registration-enabling cohort of the Phase 2 KRYSTAL-1 study,
Mirati Therapeutics Announced Clinical Data with Investigational Adagrasib Showed Adagrasib Alone and With Cetuximab Demonstrated Significant Clinical Activity and Broad Disease Control in Patients with KRAS G12C-Mutated Colorectal Cancer; Data to be…
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced results from a cohort of the Phase 1/2 KRYSTAL–1 study evaluating adagrasib at the 600mg BID dose as both monotherapy and in combination with cetuximab in patients with heavily pretreated colorectal cancer harboring a KRASG12C mutation.
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical readouts and IPOs were among the catalysts for the week.
Mirati Therapeutics To Host Virtual Investor Event Monday, Sept. 20, 2021
Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, today announced that the Company will host a virtual Investor Event on Monday, September 20, 2021 at 8:30
Morgan Stanley Initiates Coverage On Mirati Therapeutics with Equal-Weight Rating, Announces Price Target of $160
Morgan Stanley analyst Michael Ulz initiates coverage on Mirati Therapeutics (NASDAQ:MRTX) with a Equal-Weight rating and announces Price Target of $160.